A new product from Varian Medical Systems, called Acuity, promises ultraprecise targeting of cancer. Acuity integrates planning, simulation, and verification software for radiation therapy. The FDA-cleared product is designed to accelerate the adoption
A new product from Varian Medical Systems, called Acuity, promises ultraprecise targeting of cancer. Acuity integrates planning, simulation, and verification software for radiation therapy. The FDA-cleared product is designed to accelerate the adoption of intensity-modulated radiation therapy through its ability to dynamically track tumor motion during the simulation and verification process. This allows exact documentation of how tumors move as patients breathe, allowing adjustments in treatment to account for the motion. With the help of Acuity, clinics can modify plans by repositioning patients, changing treatment margins around the tumor, or by using respiratory gating to administer radiation only during specified parts of the respiratory cycle. The Acuity imaging system pairs a high-resolution x-ray tube with amorphous-silicon flat-panel image detector from Varian to instantly produce and display high-resolution radiographic and fluoroscopic digital images on a computer workstation. This speeds the simulation and verification process by eliminating film processing and by providing increased flexibility in positioning patients compared to traditional bulky image intensifier tubes.
As part of its effort to improve the accuracy of cancer therapy, Varian has a three-month program to retrofit clinics using GammaMed afterloaders for brachytherapy with its BrachyVision treatment planning software. The upgrade will boost GammaMed sites from 2D to high-resolution 3D planning. BrachyVision's 3D processing capabilities help guide placement of radiation sources for more precise delivery of radiation to cancers of the cervix, lung, prostate, breast, and head and neck.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.